Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients.
Fiche publication
Date publication
janvier 2022
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr FEIN Francine, Dr VERNEREY Dewi, Dr VIENOT Angélique, Dr KIM Stephano
Tous les auteurs :
Orillard E, Henriques J, Vernerey D, Almotlak H, Calcagno F, Fein F, Fratté S, Jary M, Klajer E, Vienot A, Borg C, Kim S
Lien Pubmed
Résumé
Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma (GEA). However, the effect of taxanes combined with platin-5FU + trastuzumab (PFT) is understudied.
Mots clés
HER2, gastric carcinoma, metastatic, survival, taxanes, trastuzumab
Référence
Front Oncol. 2022 ;12:763926